Working… Menu

NeoVax With Nivolumab in Patients With Ovarian Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04024878
Recruitment Status : Not yet recruiting
First Posted : July 18, 2019
Last Update Posted : July 18, 2019
United States Department of Defense
Information provided by (Responsible Party):
Patrick Ott, MD, Dana-Farber Cancer Institute

No Study Results Posted on for this Study
Recruitment Status : Not yet recruiting
Estimated Primary Completion Date : January 31, 2021
Estimated Study Completion Date : January 31, 2026